Hirano H, Day J, Fibiger H C
Department of Psychiatry, University of British Columbia, Vancouver, Canada.
J Neurochem. 1995 Sep;65(3):1139-45. doi: 10.1046/j.1471-4159.1995.65031139.x.
The extent to which serotonin regulates the activity of cortically projecting cholinergic neurons was studied using in vivo microdialysis to monitor interstitial concentrations of acetylcholine in the frontal cortex of freely moving rats. Systemic administration of the serotonin release-inducing agent fenfluramine (3 or 10 mg/kg, i.p.) increased acetylcholine release by 110-130%. The fenfluramine-induced increase in acetylcholine release was significantly attenuated by pretreatment with the selective serotonin uptake inhibitor fluoxetine (10 mg/kg, i.p.). Pretreatment with the selective dopamine D1 receptor antagonist SCH-23390 (0.3 mg/kg, s.c.) failed to prevent the fenfluramine-induced increase in acetylcholine release. In contrast, the serotonin 5-HT2A receptor antagonist ketanserin (5 mg/kg, i.p.) blocked fenfluramine-induced increases in acetylcholine release. In contrast to previous studies that have concluded that serotonin has inhibitory actions on cortical acetylcholine release, the present results indicate that fenfluramine increases cortical acetylcholine release in vivo by its ability to enhance serotonin transmission and that serotonin produces these effects at least in part via actions at serotonin 5-HT2A receptors.
利用体内微透析技术监测自由活动大鼠额叶皮质中乙酰胆碱的间质浓度,研究了血清素调节投射至皮质的胆碱能神经元活动的程度。系统性给予血清素释放诱导剂芬氟拉明(3或10毫克/千克,腹腔注射)可使乙酰胆碱释放增加110 - 130%。选择性血清素摄取抑制剂氟西汀(10毫克/千克,腹腔注射)预处理可显著减弱芬氟拉明诱导的乙酰胆碱释放增加。选择性多巴胺D1受体拮抗剂SCH - 23390(0.3毫克/千克,皮下注射)预处理未能阻止芬氟拉明诱导的乙酰胆碱释放增加。相比之下,血清素5 - HT2A受体拮抗剂酮色林(5毫克/千克,腹腔注射)可阻断芬氟拉明诱导的乙酰胆碱释放增加。与先前得出血清素对皮质乙酰胆碱释放具有抑制作用的研究相反,目前的结果表明,芬氟拉明通过增强血清素传递的能力在体内增加皮质乙酰胆碱释放,且血清素至少部分通过作用于血清素5 - HT2A受体产生这些效应。